Regarding baricitinib, there is a study published by Harigai et al. in 2020 which included 215 HBsAg-negative/anti-HBc-positive patients with rheumatoid arthritis (201 with positive anti-HBs; 14 with isolated anti-HBc and undetectable HBV DNA at baseline). Here, KRT88P is linked to rheumatoid arthritis.